IL Chicago의 흑색종 임상 시험
흑색종 관련 연구 15개가 Chicago 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
피험자 모집 중2상
- University of Illinois Cancer Center, Chicago
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
피험자 모집 중2상
- Northwestern University, Chicago
- University of Illinois, Chicago
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
피험자 모집 중3상
- Northwestern University, Chicago
- Swedish Covenant Hospital, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
피험자 모집 중관찰 연구건강한 지원자 환영
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- 외 1개
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
피험자 모집 중1/2상
- Northwestern University, Chicago
Project: Every Child for Younger Patients With Cancer
피험자 모집 중관찰 연구
- Lurie Children's Hospital-Chicago, Chicago
- Northwestern University, Chicago
- University of Illinois, Chicago
- 외 1개
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
피험자 모집 중1/2상
- Lurie Children's Hospital-Chicago, Chicago
Sun Exposure and Activities After Skin Cancer: Optimization of mHealth Interventions
피험자 모집 중
- Northwestern University, Chicago
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
피험자 모집 중1/2상
- Call for Information (Investigational Site 0024), Chicago
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
피험자 모집 중1/2상
- University of Chicago Medical Center, Chicago
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
피험자 모집 중1/2상
- University of Chicago, Chicago
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
피험자 모집 중2/3상
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
피험자 모집 중관찰 연구
- John H Stroger Jr Hospital of Cook County, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
피험자 모집 중관찰 연구
- Massive Bio SYNERGY-AI site, Chicago
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
피험자 모집 중
- Advocate Illinois Masonic Medical Center, Chicago
다른 도시의 흑색종 시험
- Houston, TX연구 59개
- New York City, NY연구 38개
- Los Angeles, CA연구 34개
- Nashville, TN연구 32개
- Pittsburgh, PA연구 31개
- Boston, MA연구 25개
- Philadelphia, PA연구 23개
- San Francisco, CA연구 22개
- Salt Lake City, UT연구 21개
- Columbus, OH연구 21개
- Atlanta, GA연구 21개
- Arlington, VA연구 20개
Chicago의 다른 연구
- 비소세포폐암연구 62개
- 유방암연구 58개
- 암 (전체)연구 52개
- 전립선암연구 45개
- 전이성 암연구 45개
- 폐암연구 41개
- 비만연구 41개
- 난소암연구 37개
- 뇌졸중연구 35개
- 심부전연구 32개
- 대장직장암연구 32개
- 과체중연구 27개
ClinicalTrials.gov 출처, 2026. 9. 29. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.